Novel therapies in advanced renal cell carcinoma: Management of adverse events of sorafenib and sunitinib;Neue therapien beim fortgeschrittenen nierenzellkarzinom: Der umgang mit unerwünschten arzneimittelwirkungen von sunitinib und sorafenib

Deutsches Arzteblatt

Volumn 105, Issue 13, 2008, Pages 232-237

  Ivanyi, Philipp ^a   Winkler, Thomas ^a   Ganser, Arnold ^a   Reuter, Christoph ^a   Grünwald, Viktor ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Kinase inhibitor; Molecular targeted therapy; Renal cell cancer; Sorafenib; Sunitinib

Indexed keywords

SORAFENIB; SUNITINIB;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE SEVERITY; HUMAN; INFLAMMATION; KIDNEY CARCINOMA; LASSITUDE; PATIENT SAFETY; SKIN TOXICITY;

EID: 41949101493     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2008.0232     Document Type: Article

References (20)

1. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 2005; 23: 2477-90.
2. Brugarolas J: Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 2007; 2: 185-7.
3. Müller-Tidow C, Krug U, Brunnberg U, Berdel WE, Serve H: Tyrosinkinasen als Ziele neuer onkologischer Therapien. Dtsch Arztebl 2007; 19: 1312-9.
4. Motzer RJ, Hutson TE, Tomczak P et al.: Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma. N Engl J Med 2007; 2: 115-24.
5. Escudier B, Eisen T, Stadler WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 2: 125-34.
6. Verheul HM, Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 6: 475-85.
7. Gore M, Porta C, Oudard S et al.: Sunitinib in metastatic renal cell carcinoma (mrcc): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol ASCO Annual Meeting Proceedings 2007; 25: 5010.
8. Drabkin HA, Figlin RA, Stadler WM et al.: The advanced renal cell carcinoma sorafenib (arccs) expanded access trial: safety and efficacy in patients (pts) with prior bevacizumab (bev) treatment. J Clin Oncol ASCO Annual Meeting Proceedings 2007; 25: 5041-7.
9. Ratain MJ, Eisen T, Stadler WM et al.: Phase-II-placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 16: 2505-12.
10. Faivre S, Delbaldo C, Vera K et al.: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 1: 25-35.
11. Senior K: Fatigue with sunitinib-induced hypothyroidism. Lancet Oncol 2007; 2: 101.
12. Wolter P, Dumez H, Schöffski P: Sunitinib and hypothyroidism. N Engl J Med 2007; 15: 1580.
13. Tsai KY, Yang CH, Kuo TT, Hong HS, Chang JW: Hand-foot-syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006; 36: 5786-8.
14. Strumberg D, Clark JW, Awada A et al.: Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 4: 426-37.
15. Veronese ML, Mosenkis A, Flaherty KT et al.: Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 9: 1363-9.
16. Desai J, Yassa L, Marqusee E et al.: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 9: 660-4.
17. Wong E, Rosen LS, Mulay M et al.: Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007; 4: 351-5.
18. Rini BI, Tamaskar I, Shaheen P et al.: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;1:81-3.
19. Tamaskar IR, Unnithan J, Garcia JA, et al.: Thyroid function test (TFT) abnormalities in patients with metastatic renal cell carcinoma (RCC) treated with sorafenib. J Clin Oncol ASCO Annual Meeting Proceedings 2007; 25: 5048.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr. et al.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the jnc 7 report. Jama 2003; 289: 2560-72.